Opinion|Videos|January 25, 2024
Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM
Author(s)Amir Ali, PharmD, BCOP
Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
4
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
5